Copyright © 2022 StrategyHelix Inc. All Rights Reserved.
Global Ophthalmic Implants Market - Outlook and Forecast 2022-2027
The ophthalmic implants market had a valuation of USD 4 billion in 2021, and it is projected to reach USD 7 billion by 2027, with a compound annual growth rate (CAGR) of 6.5%.
According to a market research report, the ophthalmic implants market is expected to grow moderately between 2021 and 2027. This growth is attributed to the high prevalence of eye diseases in emerging and developing countries. Refractive errors, cataracts, age-related macular degeneration, glaucoma, diabetic retinopathy, corneal opacity, and trachoma are the main causes of poor eyesight. Cataracts and uncorrected refractive errors are the leading causes of blindness, which are more prevalent in low- and middle-income countries. On the other hand, developed countries have higher rates of diabetic retinopathy, glaucoma, and age-related macular degeneration.
|No. of Pages||
USD 4.7 billion in 2020
Product, Application, End-User, and Geography
|No. of Companies Mentioned||
The global ophthalmic implants market is expected to grow remarkably at a CAGR of 6.5% during the forecast period. This growth is driven by the increased demand for ophthalmic implants in the treatment of eye diseases such as glaucoma and diabetic retinopathy.
Factors contributing to the growth of the global ophthalmic implants market include the rise in the frequency of eye diseases and the growing geriatric population, who are more susceptible to eye ailments. Additionally, the increasing number of regulatory approvals for ocular devices enables large companies to generate significant revenue in the ocular implant market.
To maintain market share, key players in the industry adopt strategies such as agreements and collaborations with other industry players. For instance, the STAAR Surgical Corporation entered into a cooperation agreement with the World Eye Hospital Group, making it the largest provider of refractive surgery treatment solutions in Southeastern Europe. This strategic collaboration is expected to create lucrative opportunities during the forecast period.
Technological advancements and the adoption of vision correction methods, along with the increasing use of intraocular lenses in cataract surgery, are driving the growth of the ophthalmic implants market. For example, a new collagen glaucoma implant has been developed to inhibit scarring and is biodegradable.
Eye research institutes play a crucial role in the technological advancement of intraocular lenses. The report provides information on various categories within the ophthalmic implants market. It also includes critical information on market growth and current trends in ocular implants over the forecast year.
Increasing investments in research and development of new products, such as ocular implants for drug delivery, will have a direct impact on the growth of the ophthalmic implants market in the coming years. Advances in ophthalmic diagnostic technology have led to wider product adoption. The accessibility of online tools has also increased public awareness of various treatment options, contributing to market growth. The acceptance of advanced ocular devices like artificial eyes and glaucoma devices has created significant potential for companies in the industry.
Refractive lens implants are used to improve vision rather than just correcting clouded vision caused by cataracts. For example, toric intraocular lenses correct astigmatism and provide spectacle-free farsighted vision. The use of portable medical devices for home-based diagnosis and treatment of eye diseases is increasing, allowing for convenient diagnosis and monitoring. Medical devices equipped with artificial intelligence and machine learning can quickly interpret retinal scans with greater accuracy and recommend suitable treatments.
As most of the affected individuals are in the geriatric age group (over 50 years old), investments in ophthalmic diagnostics have increased. Technological innovations have greatly impacted the healthcare industry, including ophthalmology. The introduction of optical coherence tomography (OCT) has transformed eye care. The growing advances in ophthalmic diagnostic technology are expected to drive the industry during the forecast period.
According to the Center for Disease Control and Prevention (CDC), age-related eye injuries, such as age-related macular degeneration, cataracts, diabetic retinopathy, and glaucoma, are the leading causes of low vision and blindness in the US. Other common eye diseases include amblyopia and strabismus. In the US, approximately 4.2 million individuals aged 40 and older are either legally blind or partially sighted. The National Eye Institute states that refractive surgery could improve the eyesight of 150 million Americans. In 2020, an estimated 1.8 million Americans aged 40 were affected by age-related macular degeneration (AMD), and an additional 7.3 million individuals with large drusen were at significant risk of developing AMD.
According to the World Health Organization (WHO), around 2.2 billion people worldwide have visual impairments. Nearly half of these cases, or 1 billion people, could have prevented or unresolved visual impairments. Among this group, 88.4 million have moderate or severe distance vision disorders or blindness due to unaddressed refractive errors, 94 million have cataracts, 7.7 million have glaucoma, 4.2 million have corneal opacities, 3.9 million have diabetic retinopathy, and 2 million have trachoma. An additional 826 million people have near vision impairment due to unaddressed presbyopia. Advances in diagnostic technologies and research and development of new therapeutics for these disorders are expected to fuel market growth.
The market is segmented based on various factors, including product, application, end-user, and geography.
Segmentation by Product
Segmentation by Application
Segmentation by End-User
Ambulatory Surgery Centers
Segmentation by Geography
North America – US, Canada
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan, India, South Korea, Australia
Latin America – Brazil, Mexico, Argentina
Middle East & Africa – South Africa, Saudi Arabia, Turkey
The Ocular Implants Market is divided into segments based on product, application, end-user, and region.
Among these segments, Intraocular Lenses are anticipated to experience the highest incremental growth, while Glaucoma Implants are expected to witness the highest absolute growth within the forecast period. The increasing prevalence of conditions such as presbyopia, myopia, blindness, cataract surgery, and farsightedness is projected to drive the demand for eye implants globally. Additionally, factors such as growing awareness of comprehensive eye care services, a surge in the geriatric population, and the inclusion of eye care services in insurance systems contribute to market growth. An important factor impacting players in the intraocular lens industry is the significant increase in the number of patients undergoing cataract surgery over the past decade.
Cataract Surgery holds the largest share in the market, followed by Glaucoma Surgery, which is expected to witness the highest absolute growth within the forecast period. Optical surgeons treat glaucoma using either conventional glaucoma surgery or minimally invasive glaucoma surgery. In the United States alone, approximately 2.7 million people aged 40 and above have open-angle glaucoma, 3.3 million suffer from blindness or vision loss, and over 3 million Americans have glaucoma. The increasing prevalence of glaucoma worldwide, coupled with the global aging population, contributes to the growth of the cataract surgery market. Increasing awareness of the treatment of this disease, advancements in healthcare infrastructure, and innovative product technologies further drive the expansion of the global ophthalmic implants market.
According to Alcon Inc., cataracts are the leading cause of vision loss on a global scale. It is estimated that by 2025, around 5.4 million cataract surgeries will be performed in the United States alone. The increasing prevalence of cataracts and technological advancements in ophthalmic devices are key drivers of market growth. Additionally, the global growth of the elderly population plays a significant role in driving industry expansion. However, the lack of health insurance coverage and low awareness of the benefits of cataract surgery may act as barriers for the ophthalmic implants market.
Hospitals are expected to experience the highest incremental growth during the forecast period and remain the dominant segment in the ophthalmic implant market. Glaucoma drainage implant surgeries are typically performed in outpatient surgery centers or hospitals, with the procedure usually taking about an hour or less. Hospitals are well-equipped for surgical procedures and provide comprehensive preoperative and postoperative care, making them the preferred choice for patients. Therefore, the increasing number of patients seeking treatment in hospitals is expected to drive market growth.
In the North American region, the increasing aging population and growing awareness are expected to drive the ophthalmic implants market size. According to the Population Reference Bureau, the number of Americans aged 65 and over is projected to nearly double from 52 million in 2018 to 95 million in 2060, accounting for 16% to 23% of the total population. As the population ages, the demand for cataract and glaucoma surgeries is on the rise. The National Eye Institute (NEI) is leading research efforts to better prevent, detect, and treat these potentially devastating diseases. In the early stages, glaucoma often presents no symptoms, and once vision is lost in the later stages, it cannot be restored. Therefore, awareness of eye diseases is driving and accelerating the demand for implants in the region. Furthermore, product approvals and launches in North America will aid in market penetration. For example, in September 2020, Roche’s Genentech unit launched an eye implant designed to facilitate the use of Lucentis for macular degeneration. North America is expected to witness the highest incremental growth, while the Asia-Pacific region is likely to experience the highest absolute growth during the forecast period.
The adoption of ophthalmic diagnostic technology has witnessed significant advancements, leading to increased product adoption. The widespread availability of online tools has effectively educated the public about various treatment options, thereby contributing to market growth. The rising acceptance of advanced ocular devices, such as artificial eyes and glaucoma devices, has created opportunities for companies operating in this market. Moreover, the growing number of regulatory approvals for corneal implant devices is expected to enable large companies to generate substantial revenue within the eye implant market in the coming years.
The market is further expected to experience growth due to the introduction of advanced intraocular lenses and intensified competition among manufacturers striving for lens enhancement. Additionally, increased investments in eye research institutes by both governmental and non-governmental organizations contribute to the fueling of market growth. Encouragingly, a surge in clinical studies pertaining to these lenses, coupled with augmented government spending on research and development activities, suggests promising growth prospects within the market.
The Prominent players in the market are Alcon, Bausch & Lomb, Carl Zeiss, Johnson & Johnson and the other prominent key players are STAAR Surgical, MORCHER GmbH, Novartis AG, Pfizer Inc., OSD Medical GmbH, Ophtec BV, PhysIOL, Hoya Surgical Optics, Rayner Intraocular Lenses Limited, SAV-IOL SA., Glaukos, Second Sight, Allergan and many among the others.
Key companies profiled in this report include ALCON, Johnson & Johnson, Bausch & Lomb, Second Sight, Micro Engineering Solutions, Gulden Ophthalmic, AJL Ophthalmic S.A, EyeD Pharma, Care Group, F. Ad. Müller Söhne Gmbh & Co.KG, Hoya Corporation, MORCHER GmbH, Ophtec BV, BVI, Rayner Intraocular Lenses Limited, Glaukos Corporation, CorNeat Vision, HumanOptics, Omni Lens, IVANTIS, InnFocus, POLYACTIVA PTY LTD, LAMBDAVISION, SMR OPHTHALMIC PVT. LTD, Labtician Ophthalmics, Inc, Devine Meditech, Innolens, iSTAR Medical.
Recent Industry Developments
In May 2020, the announcement was made regarding the launch of the LuxSmart intraocular lens (IOL) for presbyopia correction, along with its monofocal version LuxGood. These IOLs feature pre-loaded delivery systems and incorporate Pure Refractive Optics (PRO) technology.
In January 2021, the AcrySof IQ Vivity IOL (Vivity), a non-diffractive intraocular lens with extended depth of field, was introduced in the United States. This IOL is utilized within the AcrySof IQ IOL system.
In March 2020, the FDA granted approval for Allergan’s DURYSTA (bimatoprost implant) for the purpose of reducing intraocular pressure in patients diagnosed with open-angle glaucoma or ocular hypertension.
Key Questions Answered
What is the market size and growth rate of the ophthalmic implants market?
The ophthalmic implants market is projected to reach USD 7 billion by 2027, with a compound annual growth rate (CAGR) of 6.5% during the forecast period.
Which region holds the largest share in the ophthalmic implants market?
North America holds the largest share in the ophthalmic implants market.
What are the factors driving the growth of the ophthalmic implants market?
The growth of the ophthalmic implants market is driven by factors such as advancements in ophthalmic diagnostic technology, increased adoption of advanced ocular devices, and greater awareness about the diagnosis and treatment of eye disorders.
What are the latest trends in the ophthalmic implants market?
The latest trends in the ophthalmic implants market include the use of artificial intelligence for the detection of diabetic retinopathy, the use of robotic surgical assistants for eye surgeries, and the development of synthetic cornea implants.
Who are the key players in the ophthalmic implants market?
The key players in the ophthalmic implants market include ALCON, Johnson & Johnson, and Bausch & Lomb.